Fractyl Health Inc’s recent filing unveils that its Chief Executive Officer Rajagopalan Harith acquired Company’s shares for reported $19999.0 on Dec 04 ’25. In the deal valued at $1.92 per share,10,416 shares were bought. As a result of this transaction, Rajagopalan Harith now holds 501,745 shares worth roughly $1.01 million.
Then, Royan Ajay bought 17,901 shares, generating $22,980 in total proceeds. Upon buying the shares at $1.28, the Director now owns 17,901 shares.
Before that, Barnes Kelly Ann bought 31,000 shares. Fractyl Health Inc shares valued at $40,210 were divested by the Director at a price of $1.30 per share. As a result of the transaction, Barnes Kelly Ann now holds 31,000 shares, worth roughly $62309.99999999999.
H.C. Wainwright initiated its Fractyl Health Inc [GUTS] rating to a Buy in a research note published on September 15, 2025; the price target was $9. A number of analysts have revised their coverage, including Ladenburg Thalmann’s analysts, who began to cover the stock in late August with a ‘”a Buy”‘ rating. Evercore ISI began covering GUTS with “an Outperform” recommendation on February 28, 2024. Morgan Stanley started covering the stock on February 27, 2024. It rated GUTS as “an Overweight”.
Price Performance Review of GUTS
On Tuesday, Fractyl Health Inc [NASDAQ:GUTS] saw its stock jump 0.50% to $2.01. Over the last five days, the stock has gained 0.50%. Fractyl Health Inc shares have risen nearly 8.65% since the year began. Nevertheless, the stocks have fallen -8.64% over the past one year.
How much short interest is there in Fractyl Health Inc?
A steep rise in short interest was recorded in Fractyl Health Inc stocks on 2025-12-31, growing by 2.82 million shares to a total of 11.89 million shares. Yahoo Finance data shows the prior-month short interest on 2025-11-28 was 9.07 million shares. There was a rise of 23.73%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on February 27, 2024 when BofA Securities began covering the stock and recommended ‘”a Buy”‘ rating along with a $26 price target.
